Calcipotriene
DOVONEX
What it isVitamin D-receptor agonist normalizing keratinocyte proliferation; plaque psoriasis.
Why this oneIt is steroid-sparing and suitable for longer use where topical corticosteroids would cause atrophy.
What limits itIrritation is worst on the face and flexures; treating large areas can cause hypercalcemia.
FDA-approved for
- plaque psoriasis (1993)
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Plaque psoriasis (topical) | Adults | Apply thin layer QD–BID | Apply thin layer QD–BID |
Renal Undefined
Hepatic Undefined
Instructions
- Apply a thin layer and rub in gently and completely
- Do not use on the face
Contraindications
- Demonstrated hypercalcemia or evidence of vitamin D toxicity
- Do not use on the face
Cautions
- Local skin irritation (burning, itching)
- Hypercalcemia with excessive use
- Facial/scalp psoriasis worsening reported — avoid facial application
Adverse reactions
- Burning
- Itching
- Skin irritation
- Erythema
- Dry skin, peeling, rash, dermatitis
- Worsening of psoriasis
Pregnancy Pregnancy Category C; use only if potential benefit justifies potential fetal risk
Lactation Undefined
NO BOXED WARNINGS
Principal riskIrritation; hypercalcemia over large areas
Cost, est. cash$10–$300/month
Generic entry2008
Classes and tags
Clinical profile
Legacy pregnancy categoryUnknown / historical label unavailable
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.
Mechanism of action: Calcipotriene ballicule
Open Calcipotriene in the interactive console ↗
Memory aids: mascots and interaction avatars
topical psoriasis medication